mifepristone Supreme – Danco urges the Supreme Court to pause a ruling that would restrict mifepristone to in-person dispensing nationwide.
A fight over how abortion pills are delivered is now headed to the Supreme Court, with one of the drug’s manufacturers asking the nation’s top justices to pause a lower-court ruling.
Misryoum reports that Danco Laboratories asked the Supreme Court on Saturday to block an order from a federal appeals court that reinstated an in-person dispensing requirement for mifepristone. the active ingredient in a widely used medication abortion drug.. The company is also seeking an immediate pause while the justices weigh its appeal.
In its filing, Danco argued it has been able to rely on existing FDA procedures for distributing its product and said the appeals court decision would create immediate disruption and confusion if allowed to remain in effect.
This matters because the availability of medication abortion often depends not just on legal rulings, but on practical access points like pharmacies, appointments, and whether patients can use telehealth or mail delivery—especially in states where abortion access is restricted.
The appeals court decision followed a request from the state of Louisiana to revive an older requirement that would bar distribution of abortion pills through telehealth or the mail.. Misryoum reports that the change is being framed as a major shift from how the drug has been accessed. particularly for people in states with abortion bans.
Medication abortions have become a majority of abortions in the United States. and mail or remote options have helped expand access for patients who cannot travel to in-person care.. After the Supreme Court overturned Roe v.. Wade in 2022, pathways such as telehealth and mail delivery took on added significance for patients navigating new state restrictions.
Misryoum notes that Planned Parenthood Action Fund leadership publicly backed Danco’s effort, arguing that the latest ruling makes it harder for patients to receive care when and where they need it. The legal dispute is also tied to how FDA guidance has evolved over time.
The case has roots in FDA policy changes that allowed mifepristone to be dispensed via telehealth and by mail. including a rule that was put in place during the COVID-19 era and later became part of the agency’s longer-term approach.. Louisiana challenged that framework, setting up the series of rulings now reaching the Supreme Court.
If the Supreme Court does not pause the appeals court decision. the impact could be immediate for patients and providers trying to operate within the shifting boundaries of federal and state authority over drug distribution.. The justices’ response may also signal how aggressively similar access questions will be handled in future cases.